Get started
Author

Katarzyna Kmiecik

Observed names: K. Kmiecik, Kmiecik, K., Kmiecik, Katarzyna
ORCID: 0000-0002-9579-9091
Observed ORCID: 0000-0002-9579-9091
OpenAlex ID: A5069480553
FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
2020 · Matthew Kraman, Mustapha Faroudi, et al. · Clinical Cancer Research · 113
Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics
2018 · Katy L. Everett, Matthew Kraman, et al. · Methods · 31
Skeletal Muscle Response to Endurance Training in IL-6−/− Mice
2015 · M. Wojewoda, K. Kmiecik, et al. · International Journal of Sports Medicine · 20
The Role of Mcl-1 inS. aureus-Induced Cytoprotection of Infected Macrophages
2013 · Joanna Koziel, Katarzyna Kmiecik, et al. · Mediators of Inflammation · 20
PDF
The Janus Face of a-Toxin: A Potent Mediator of Cytoprotection in Staphylococci-Infected Macrophages
2014 · Joanna Koziel, Daniela Chmiest, et al. · Journal of Innate Immunity · 19
PDF
Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge
2024 · M. Biddle, P. Stylianou, et al. · mAbs · 18
Effects of a single bout of strenuous exercise on platelet activation in female ApoE/LDLR−/−mice
2017 · K. Przyborowski, H. Kassassir, et al. · Platelets · 17
Running Performance at High Running Velocities Is Impaired but V′O2max and Peripheral Endothelial Function Are Preserved in IL-6−/− Mice
2014 · Marta Wojewoda, Katarzyna Kmiecik, et al. · PLoS ONE · 17
PDF
Abstract 2719: Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+ T-cell activation and modulates the tumor microenvironment to promote antitumor immune responses
2018 · Matthew Kraman, Natalie Fosh, et al. · Cancer Research · 14
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
2016 · Andreas Lundqvist, Vincent van Hoef, et al. · Journal for ImmunoTherapy of Cancer · 12
PDF
Abstract PR06: A LAG-3/PD-L1 bispecific antibody inhibits tumour growth in two syngeneic colon carcinoma models
2017 · Katy Everett, Matthew Kraman, et al. · Cancer Immunology Research · 3
Abstract B091: A LAG-3/PD-L1 bispecific antibody inhibits tumor growth in two syngeneic colon carcinoma models
2016 · Jacqueline Doody, Matthew Kraman, et al. · Cancer Immunology Research · 1
Movement and Rhythm
2026 · Kmiecik, Katarzyna · Didaskalia. Gazeta Teatralna
Kraman et al Supplementary Data from FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
2023 · Matthew Kraman, Mustapha Faroudi, et al.
PDF
Data from FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
2023 · Matthew Kraman, Mustapha Faroudi, et al.
Data from FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
2023 · Matthew Kraman, Mustapha Faroudi, et al.
Kraman et al Supplementary Data from FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
2023 · Matthew Kraman, Mustapha Faroudi, et al.
Abstract 5651: A LAG-3/PD-L1 bispecific antibody inhibits tumor growth in two syngeneic colon carcinoma models
2017 · Matthew Kraman, Katarzyna Kmiecik, et al. · Cancer Research
Supplementary Material for: The Janus Face of a-Toxin: A Potent Mediator of Cytoprotection in Staphylococci-Infected Macrophages
2017 · Koziel, J., Chmiest, D., et al. · Figshare
Works count: 20
Citation count: 285
H-index: 10
I10-index: 10
Year
Topic
Type